60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
In an exclusive interview, Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to combat infectious diseases with innovative, small-molecule therapeutics. Dow highlights the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He also outlines 60 Degrees Pharmaceuticals' strategy to repurpose tafenoquine for other serious infectious diseases, including babesiosis-a growing tick-borne illness with tens of thousands of new U.S. cases annually. With two potentially pivotal clinical trials underway, a third study in the final planning stages, and a strong foundation of IP, regulatory experience, and institutional support, 60 Degrees Pharmaceuticals is advancing a cost-effective, scalable model for addressing unmet needs in global infectious disease treatment.
Pete O'Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company's dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star's 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development. The company's experienced leadership and strategic positioning in one of North America's most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success.
SXTP and LBSR are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA ® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
About Liberty Star
Liberty Star Uranium & Metals Corp. (OTCQB:LBSR), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently, the company controls properties that are located over what management considers some of North America's richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company's premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA.
Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations
'Discovering Tomorrow's Blue Chips Today'™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
SOURCE: RedChip Companies, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating
CG Oncology, Inc. (NASDAQ:CGON) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 17, Morgan Stanley raised the firm's price target on CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52, while maintaining an Overweight rating on the shares. A researcher in a laboratory examining a vial of oncolytic herpes simplex virus, demonstrating the company's commitment to finding a cure for cancer. The firm told investors in a research note that although the non-muscle invasive bladder cancer space has undergone recent and anticipated approvals, the space is comprehensive enough to accommodate multiple players. It thus considers cretostimogene to be meaningfully differentiated by its safety data and durability, along with having 'best-in-disease potential' that supports an optimistic rating for the company. CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for bladder cancer. Its product cretostimogene is initially in clinical development for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market?
This company has reported accelerating revenue growth in recent quarters, and in the latest period, revenue soared more than 150%. After great gains last year, the stock slipped 45% in the first half of this year. 10 stocks we like better than SoundHound AI › Last year was a big one for artificial intelligence (AI) stocks, with companies in the sector leading all three major benchmarks to gains. Though the momentum halted temporarily earlier this year, as investors worried about the impact of import tariffs on the economy, this positive energy has returned. Investors are optimistic that trade talks will result in lower-than-expected tariffs, limiting the negative effects on companies, and that has buoyed interest in growth players, including AI stocks. Some AI stocks, though, have yet to feel the rebound. Considering the long-term AI growth story hasn't changed, these players may offer you bargain buying opportunities today. Let's consider one in particular. This AI stock surged more than 800% in 2024 but dropped 45% in the first half of this year. Meanwhile, it's a specialist in its field, one with a total addressable market of more than $140 billion. Is this player a buy right now? The AI stock I'm talking about is SoundHound AI (NASDAQ: SOUN), a company with expertise in voice AI, reinforced by more than 190 granted patents. Though other companies, even big players such as Amazon or Microsoft, are involved in the field, SoundHound stands out thanks to its speech-to-meaning technology. The company translates speech directly to meaning, bypassing the common step of translating speech to text first, therefore gaining in speed and quality. Customers clearly like SoundHound's offerings, as revenue has taken off, and the company has signed deals across industries. This is a key point because, in its earlier days, SoundHound primarily served the automobile industry. This strength in fields such as healthcare, retail, travel, and more, as well as the fact that no customer represents more than 10% of revenue, greatly reduces SoundHound's risk. That's because if one customer or industry cuts spending, others may compensate. SoundHound's revenue in the recent quarter advanced 151% to about $29 million, which is great. But what's even better is that the company still has plenty of room for growth, considering its current revenue level and the total addressable market of $140 billion, which spans 14 different industries. And the company has three ways to generate revenue: through royalties on its products, subscriptions for services, and taking additional revenue from the use of its products and services. Of course, despite SoundHound's expertise in the field, the company still faces the risk of major rivals, such as those mentioned above, gaining market share due to their immense resources. That's what makes SoundHound a stock that carries some risk right now, and even though the stock has slipped this year, the decline looks small compared to the gain posted last year. These factors could limit SoundHound's growth in the near term. Still, the company has seen growth accelerate in recent quarters, from 89% in the third quarter of last year to 101% in the fourth quarter and even higher in the most recent period. Further, as mentioned above, SoundHound may still be in its early stages of growth. So, what does this mean for you as an investor? Should you buy SoundHound now on the dip? The answer depends on your investment strategy. If you're a cautious investor, you're probably better off buying a larger, well-established player, such as Amazon or Microsoft, that may benefit from voice AI but also from broader, profitable businesses. Over time, they've proven their earnings and stock performance strengths. If you're an aggressive investor, though, SoundHound looks like a fantastic AI buy right now. The stock has slipped from its high, offering you a lower entry point. Revenue has clearly accelerated in recent quarters, and the company has successfully broadened its customer base across industries. On top of that, I like that SoundHound is financially healthy, with no debt and $246 million in cash. All this makes it a great AI stock to get in on right now and hang on to as its growth story develops. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
